Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07549061 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
To explore the efficacy and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver gene-negative, locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression.
Trial Details
NCT Number NCT07549061
Lead Sponsor Shanghai Chest Hospital
Conditions
(from sponsor)		 Lung Neoplasms
Related terms Lung Neoplasms
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov